Risk of Non-AIDS-Related Mortality May Exceed Risk of AIDS-Related Mortality Among Individuals Enrolling Into Care With CD4+ Counts Greater Than 200 Cells/mm3

Objective:To quantify cause-specific mortality risk attributable to non-AIDS-related and AIDS-related causes before and after the advent of highly active antiretroviral therapy (HAART). Methods:Competing-risk methods were used to determine the cumulative AIDS-related and non-AIDS-related risk of mortality between 1990 and the end of 2003 in the Johns Hopkins HIV Clinical Cohort, a prospective cohort study. Results:Beginning in 1997 with the introduction of HAART, all-cause mortality declined and has remained stable at approximately 39 deaths per 1000 person-years. AIDS-related mortality continued to decline in this period (P = 0.008), whereas non-AIDS-related mortality increased (P < 0.001). Using competing-risk methods, the risk of dying attributable to AIDS-related causes remains significantly higher than the risk of dying attributable to non-AIDS-related causes for patients with a CD4+ count ≤200 cells/mm3 in the HAART era. For those with a CD4+ count >200 cells/mm3, however, non-AIDS-related mortality was greater than AIDS-related mortality, particularly among injection drug users. Other transmission categories had similar AIDS-related and non-AIDS-related cumulative mortalities. Conclusions:HAART has reduced mortality rates among HIV-infected individuals, but further efforts to reduce mortality in this population require increased attention to conditions that have not traditionally been considered to be HIV related.

[1]  Kholoud Porter,et al.  Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion , 2006, AIDS.

[2]  P. Morlat,et al.  Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. , 2004, International journal of epidemiology.

[3]  A. Mocroft,et al.  Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy , 2004, AIDS.

[4]  D. Vlahov,et al.  Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. , 2004, The Journal of infectious diseases.

[5]  M. Zwahlen,et al.  All cause mortality in the Swiss HIV cohort study from 1990 to 2001 in comparison with the Swiss population , 2004, AIDS.

[6]  Mark A van de Wiel,et al.  Mortality and progression to AIDS after starting highly active antiretroviral therapy , 2003, AIDS.

[7]  D. Vlahov,et al.  Longitudinal patterns of drug injection behavior in the ALIVE Study cohort,1988-2000: description and determinants. , 2003, American journal of epidemiology.

[8]  J. Sterne,et al.  Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies , 2003, The Lancet.

[9]  A. Mocroft,et al.  Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.

[10]  A. Mocroft,et al.  Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study , 2002, AIDS.

[11]  Mary Young,et al.  Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. , 2002, The American journal of medicine.

[12]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[13]  R. Byers,et al.  Trends in Diseases Reported on U.S. Death Certificates That Mentioned HIV Infection, 1987‐1999 , 2002, Journal of acquired immune deficiency syndromes.

[14]  R. Byers,et al.  Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. , 2002 .

[15]  M. Lederman,et al.  Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995--1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Anne M Johnson,et al.  A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. , 1999, Journal of acquired immune deficiency syndromes.

[17]  R. Chaisson,et al.  Natural history of HIV infection in the era of combination antiretroviral therapy. , 1999, AIDS.

[18]  J. Ward,et al.  Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. , 1999, AIDS.

[19]  D. Revicki,et al.  Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter , 1999 .

[20]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[21]  D. Revicki,et al.  A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease , 1998, AIDS.

[22]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[23]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[24]  Manuel Battegay,et al.  Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.

[25]  M Lunn,et al.  Applying Cox regression to competing risks. , 1995, Biometrics.

[26]  Jeffrey J. Gaynor,et al.  On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data , 1993 .

[27]  D. Cox,et al.  THE ANALYSIS OF EXPONENTIALLY DISTRIBUTED LIFE-TIMES WITH Two TYPES OF FAILURE , 1959 .

[28]  R. Moore,et al.  Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[29]  B. Efron.  The jackknife, the bootstrap, and other resampling plans , 1987 .